Jeffrey S. Miller

发表

Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer

Philippa R. Kennedy, M. Felices, Jeffrey S. Miller, 2022, Stem cell research & therapy.

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity

M. Geller, Y. Soignier, T. Lenvik, 2022, Journal for ImmunoTherapy of Cancer.

Adaptive NK cell and KIR-expressing T cell responses are induced by CMV and are associated with protection against CMV reactivation after allogeneic donor hematopoietic cell transplantation Blood Marrow Transplant .

P. Parham, J. Wagner, D. Weisdorf, 2015 .

Bispeci ﬁ c and Trispeci ﬁ c Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

L. Weiner, D. Vallera, D. Todhunter, 2012 .

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

M. Uhrberg, S. Bhatia, D. Vallera, 2021, Cancer Immunology, Immunotherapy.

Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia

H. Ljunggren, E. Alici, P. Blomberg, 2022, Journal for immunotherapy of cancer.

Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion

M. Felices, P. Hinderlie, L. Bendzick, 2022, JCI insight.

Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy

M. Felices, Jeffrey S. Miller, S. Phung, 2021, Molecular Diagnosis & Therapy.

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer

M. Geller, D. Vallera, M. Felices, 2021, Cancers.

Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation

E. Turley, T. Starr, B. Moriarity, 2021, Translational oncology.

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

I. Pastan, R. Kratzke, D. Vallera, 2023, Frontiers in Immunology.

Ablation of SYK kinase from primary human Natural Killer cells via CRISPR/Cas9 enhances cytotoxicity and cytokine production

Beau R. Webber, B. Moriarity, G. Hart, 2022, bioRxiv.

Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.

Bahram Valamehr, Z. Davis, A. Witty, 2022, Blood.

Immunotherapeutic Development of a Tri-Specific NK Cell Engager Recognizing BCMA

D. Vallera, M. Felices, B. Kodal, 2023, Immuno.

Putting On the Gas and Taking Off the Brakes: A Novel Combinatorial Strategy to Enhance Tumor-Infiltrating Lymphocytes

M. Felices, Jeffrey S. Miller, 2021, Cancer Immunology Research.

Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma

Justin H Hwang, Cheng-Ying Wu, N. Snyder, 2023, Science Translational Medicine.

Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma

Sajid Mahmood, Brian Groff, Bahram Valamehr, 2021, Immunology.

Abstract 1539: Development of off-the-shelf B7H3 chimeric antigen receptor NK cell therapeutic with broad applicability across many solid tumors

Bahram Valamehr, Z. Davis, S. Gaidarova, 2021, Immunology.

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

T. Niki, M. Hirashima, Jeffrey S. Miller, 2012, Blood.